pharmaceutical setbacks
Neurocrine’s Phase 2 Depression Drug Fails Primary Endpoint in Major Takeda-Licensed Study
Neurocrine Biosciences; Takeda; NBI-1070770; Phase 2 failure; major depressive disorder; depression drug; psychiatry pipeline; clinical trial results; drug licensing; pharmaceutical setbacks